The dispute over who invented CRISPR-Cas9 gene editing is headed to federal appellate court, and Politico turned to Professor Jacob Sherkow to help sort out the details. He expects the case will return to patent court and may result in changes to the licensing fees collected. “Absolutely none of this under any reasonable interpretation is […]
Illinois Law professor and IP expert Jacob Sherkow spoke to Nature Biotechnology about the recent Tome Biosciences acquisition of Replace Therapeutics to enhance their gene editing capabilities. The article discusses the surge of prime editing deals in biotechnology as companies seek to secure patent rights and avoid intellectual property conflicts. The industry is seeing mergers […]
Professor Jacqueline E. Ross was awarded the 2024 Wayne R. LaFave Award for Scholarly Excellence for her book “Making Sense of Youth Crime: A Comparison of Police Intelligence in the United States and France,” (Cambridge University Press, 2023) co-authored with Thierry Delpeuch of the French National Centre for Scientific Research. This award was established in […]
The famous system of breaking down legal analyses into ordered subparts, Issue-Rule-Analysis-Conclusion, needs an updated focus on the last part, according to Professor Jacob Sherkow. In his new paper, available for download on SSRN, he argues that lawyers need to be experts in conclusions, writing “good conclusions – clear, reasonable, workable, plausible, probable conclusions – […]
Professor Jacob Sherkow was invited to speak at the “Regulation of Innovative Health Technologies Workshop,” which took place at the leading Centre for Law and Genetics, University of Tasmania, from November 23-25, 2023. As part of the workshop, Sherkow was the organizer of a session examining patents as regulators of innovative health technologies. The international […]
“I would be surprised, bluntly, if [a lawsuit] does not get filed by the end of this year,” Professor Jacob Sherkow told Politico about the patent battle over CRISPR technology. When the FDA issued approval for the therapy in sickle cell cases, it granted approval to companies that do not hold licenses for CRISPR. As […]
Approval for Vertex Pharmaceutical’s sickle cell treatment using CRISPR technology has brought use of the gene-editing therapy to a “collision point,” according to Professor Jacob Sherkow. Speaking to the MIT Technology Review, Sherkow explained how the patent on editing human cells using CRISPR is owned by the Broad Institute of MIT and Harvard, not Vertex, […]
Professor Jacob Sherkow is a co-author on a new paper published by the National Academy of Medicine examining the rise of telehealth and the digital transformation of healthcare. The discussion paper is part of a new NAM Perspectives series explores emerging science and technology applications in order to better understand, anticipate, and develop governance for future […]
Professor Jacob Sherkow travelled to Cologne, Germany, in September to deliver a lecture as part of the CMMC Symposium in Molecular Medicine. The Symposium was titled “From Concepts to Clinic: a New Era of Nucleic Acid Therapeutics,” and aimed to provide attendees with an in-depth understanding of the chemical, biological and clinical challenges in the […]
Writing with fellow patent experts, Professors Bernard Chao and Timothy Holbrook of the University of Denver School of Law and Professor Mark A. Lemley of Stanford Law School, Professor Jacob Sherkow submitted an amicus brief to the U.S. Court of Appeals for the Federal Circuit. The brief is written in response to the decision made by the Patent Trial and […]